Tg Therapeutics (TGTX) Other financing activities (2013 - 2026)
Tg Therapeutics (TGTX) posted quarterly Other financing activities of $763000.0 for Q1 2026, up 3533.33% year-over-year from $21000.0 in Q1 2025, and down 49.5% quarter-over-quarter from $1.5 million in Q4 2025.
Tg Therapeutics (TGTX) Other financing activities (2013 - 2026) Analysis & Trends
Tg Therapeutics' Other financing activities history runs 13 years deep, the most recent figure standing at $763000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 3533.33% year-over-year to $763000.0; the TTM figure through Mar 2026 stood at $2.3 million (up 150.33% YoY), while the FY2025 annual figure was $1.5 million, up 69.97% from the prior year.
- Other financing activities for Q1 2026 stood at $763000.0, down from $1.5 million in the prior quarter.
- The five-year high for Other financing activities was $1.5 million in Q4 2025, with the low at -$453000.0 in Q3 2025.
- The 5-year median for Other financing activities is $281000.0 (2023), against an average of $330062.5.
- The sharpest annual moves came in 2022 and 2026: Other financing activities plunged 620.0% in 2022, then soared 3533.33% in 2026.
- Tg Therapeutics' Other financing activities stood at $584000.0 in 2022, then declined by 28.08% to $420000.0 in 2023, then grew by 29.76% to $545000.0 in 2024, then surged by 177.25% to $1.5 million in 2025, then sank by 49.5% to $763000.0 in 2026.
- Business Quant data shows TGTX's Other financing activities at $763000.0 in Q1 2026, $1.5 million in Q4 2025, and -$453000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 763,000.00 |
| Mar 31, 2026 | 763,000.00 |
| Dec 31, 2025 | 1.51 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | -453,000.00 |
| Sep 30, 2025 | -453,000.00 |
| Jun 30, 2025 | 432,000.00 |
| Jun 30, 2025 | 432,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Mar 31, 2025 | 21,000.00 |
| Dec 31, 2024 | 545,000.00 |
| Dec 31, 2024 | 545,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 135,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Mar 31, 2024 | 10,000.00 |
| Sep 30, 2023 | 420,000.00 |
| Sep 30, 2023 | 420,000.00 |